Bausch + Lomb (BLCO) stock

Eye care products , market cap $7.3B

Lenses, surgical tools, and eye medicines

Market cap $7.3B

$20.70

+3.35%

As of 11:49 AM ET, delayed 15+ min · Live for Pro members

Quality Score

Excellent

In its industry

#8of 85

Medical Devices

Checks firing

9of 14

Trending up

From 52-week high

-3.1%

Above the 200-day

BLCO's Quality Score rose 1 point on Wed, Nov 4, to 16.

See BLCO's 14 chart checksSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why is BLCO up?

Up 3.3% today with medical device stocks: Neuronetics rose 28.5% after its report; 79 of 85 are up, 6.7% on average; the S&P 500 is up 1.8%; energy and refiner stocks fell.

Rose on Oct 28

Up 16% on Oct 28, and still 14% over its Oct 27 close.

“The change was driven by revenue growth noted above and operating efficiencies.”

Bausch + Lomb's Oct 28 release said

Sources: Price history, Oct 28, 2026; Company release, Oct 28, 2026

1 more reason, free with an account →5 more reasons why BLCO rose on Oct 28, from its filings, with the company's words, the timeline, and its peers, for Pro members.

Key facts on BLCO

Key facts on BLCO
The company	Operating margin up 5.3 points on the year
Latest filing	8-K, Oct 28 Reported its quarterly results

1 more reason behind BLCO's 16, free with an account →2 more reasons behind BLCO's 16, for Pro members.

BLCO in the news

TodayWith its group.

Big story

Leadership

Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief

BLCO closed −7.1% that day on 8.2x normal volume.

Reported by Reuters · covered by 23 outlets

Get an alert on BLCO's next big story →

Outlet counts from the GDELT Project. The move is what BLCO did that session, not a claim about why.

BLCO catalysts

Coming up

After its last 4 reports it closed +2.6% on average, higher 1 of 4 times.

2 past catalysts since 2025, with sizes and sources, for Pro members.Get in free →

Why BLCO scores 16

Excellentfor quality, not price, 9 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. BLCO scores 16 today, against a median of 8.5 over its last 20 recorded sessions.

+9Chart checks 9 of 14 firing right now, one point each
+4Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, at a multi-⁠year high

Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
News adds
Insider trades subtracts

No effect today: Run-up, Size, Profit, Dilution, Volatility, Cash flow, and Persistence.

What every line is worth, and the reason behind it, on BLCO and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:49 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when BLCO's Quality Score turns up

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on BLCO and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

BLCO has 9 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on BLCO, and all 14 on every stock.Get in free →

BLCO RSI today: 77.6, above its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1477.6
70 or above.
MACD (12, 26, 9)Above signal
Crossed above its signal line 10 sessions ago.
50-day average$17.53
The price is 18.1% above it.
200-day average$16.72
The price is 23.8% above it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Aug 27.
ADX 1428.6
25 or more, with +DI above -DI.
Support$16.94
Swing low from Aug 28, 18.2% below the price.
Resistance$21.36
No swing high over the price in the last year. This is the 52-week high, 3.2% above.
52-week high$21.36
From Oct 29, 3.2% above the price.
52-week low$14.44
From Nov 20, 2025, 30.2% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $14.64 to $21.15.
Volume1.5x
Against its 20-day average, for the time of day.

The deep dive on BLCO

What it does and how it makes money4 findings"Within the next three years, the following number of U.S. patents held by us is set to expire: approximately 22 patents in 2026, approximately 37 patents in 2027 and approximately 26 patents in 2028." (10-K for fiscal 2025)SEC filing · Feb 18, 2026
Where it stands3 findingsFor Pro members3 findings on where BLCO stands: its cash, debt, and share count, for Pro members
What changed in its filings5 findings"On February, 20, 2026, the Canadian court declined to certify the action and dismissed the action against the Company." (10-Q for the quarter to Jun 30, 2026)SEC filing · Jul 29, 2026New in its "Risk Factors" this year: "Our competitors include specialty and other large pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the United States, Canada, Europe, Asia, Latin America, the Middle East, Africa and in other countries in which we market our products." (10-K for fiscal 2025)SEC filing · Feb 18, 2026, against the one of Feb 19, 2025Customer, Top Ten Products made up 56% of its revenue in fiscal 2025, up from 54% in fiscal 2024.SEC filing · Feb 18, 2026
Who holds and trades it4 findingsFor Pro members4 findings on who holds and trades BLCO, for Pro members
Against its closest peers2 peersNet income over four quarters: BLCO -$171M, COO $570M, WRBY $7.74M.

12 more findings on BLCO, each with its source, for Pro membersGet in free →

How BLCO ranks in Medical Devices

BLCO is #8 of 85 by Quality Score.

How BLCO ranks in Medical Devices
1	ATRCAtriCure	7/14	18
2	DXCMDexCom	4/14	18
3	HAEHaemonetics	7/14	17
	BAXBaxter International		Open for its score
	BDXBecton, Dickinson		Open for its score
	BSXBoston Scientific		Open for its score
	BVSBioventus		Open for its score
8	BLCOBausch + Lomb	9/14	16

Net income over four quarters: BLCO -$171M, COO $570M, WRBY $7.74M.

When does BLCO report earnings, and what happens after?

Expected to report Wed Feb 17, before the open (in 105 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What BLCO reported on Oct 28, 2026

The quarter

The figures are not read from the release yet.

“The increase in the anticipated full-year revenue is a result of a $15 million increase in the underlying business outlook, based on continued strong business performance in the third quarter of 2026 and anticipated stronger business performance for the remainder of 2026, partially offset by a decrease of $5 million in expected currency tailwinds (such decrease is a result of exchange rates moderating).”

The filing on EDGAR

Where the sales came from

BLCO's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Full-year revenue foreign exchange tailwind	$40Mcut

Figures as filed (SEC filing, Oct 28)

2 more outlook lines, for Pro members.

In the company's words

“The change was driven by revenue growth noted above and operating efficiencies.”

From its results filing (SEC filing · Oct 28)

1 more sentence, for Pro members.

The numbers

Market value: $7.3B; today
Sales: $5.3B; up 8.8% on the year
Free cash flow: $137M; last 12 months

Sales grew 8.4% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 0.2% a year over 5 years.

5 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on BLCO: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

-2.4%-2.5%+15.8%

Apr 29Jul 29Oct 28

Reported	When	Gap	Reaction	5 sessions
Oct 28, 2026Before open	Before open	+5.2%	+15.8%	+13.7%
Jul 29, 2026Before open	Before open	-2.7%	-2.5%	+0.4%
Apr 29, 2026Before open	Before open	+2.2%	-2.4%	+1.8%

BLCO closed higher after 1 of its last 4 reports.

All 4 reports, and BLCO's Quality Score going into each

BLCO sales and profit by year

Sales and profit by year

Sales grew every year from 2020 to 2025, to $5.1B. It made a profit in two of the six years.

Insiders trading BLCO

BLCO insider trades

2 insiders sold $3.5M across 4 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellFrederick Munsch$2.3MSVP, Controller and CAOat $20.48 on Oct 29, filed Nov 2

SellFrederick MunschSVP, Controller and CAO$2.3Mat $20.48 on Oct 29, filed Nov 2

All 4 insider filings on BLCO from the last six months, for Pro members.Get in free →

All BLCO insider trades

BLCO's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Brent L. SaundersChairman of the Board and CEO · 1 trade
Sam EldessoukyEVP and CFO · 1 trade
Frederick MunschSVP, Controller and CAO · 2 trades
A. Robert D. BaileyEVP & Chief Legal Officer · 1 trade
Andrew J. StewartPresident, GPIC
Luc BonnefoyPresident, Surgical
Yehia HashadEVP of R&D and CMO
Andrew C. Von EschenbachDirector · 3 trades

11 more officers and directors file at BLCO. Each page above names the rest.

See insider trades by person

About Bausch + Lomb

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.

13,000 employeesVaughanbausch.com

What Bausch + Lomb says it competes with

“Our competitors include specialty and other large pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the United States, Canada, Europe, Asia, Latin America, the Middle East, Africa and in other countries in which we market our products.”

From its annual report, SEC filing · Feb 18, 2026

2 more sentences, what it says it does, and its sales by region, for Pro membersGet in free →

BLCO's score card

Bausch + Lomb (BLCO): Quality Score 16, Excellent, #8 of 85 in Medical Devices, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would move BLCO's score: 5 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayNov 2Frederick Munsch sold BLCO$2.3M at $20.48, filed Nov 2

Alerts are optional.

See BLCO's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 4, 2026: BLCO's Quality Score is 16 (Excellent), #8 of 85 in Medical Devices. Insiders sold $3.5M in the last 6 months (Form 4).

Is BLCO a good stock to buy? What its Quality Score says

BLCO scores 16 today, which Breakaway calls Excellent. It is #8 of 85 in Medical Devices by Quality Score, with 9 of 14 chart checks firing. Up 16% on Oct 28, and still 14% over its Oct 27 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is BLCO's Quality Score?

BLCO scores 16 today, which Breakaway calls Excellent (15 to 19). That is #8 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BLCO's 16.

Are insiders buying BLCO?

2 insiders sold $3.5M across 4 filings in the last 6 months. No open-⁠market buys on record. The newest is Frederick Munsch, SVP, Controller and CAO, who sold $2.3M on Oct 29. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.